A Phase II Study of Intravesical Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-Muscle Invasive Lower Urinary Tract Urothelial Carcinoma

Trial Profile

A Phase II Study of Intravesical Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-Muscle Invasive Lower Urinary Tract Urothelial Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Sunitinib (Primary) ; BCG
  • Indications Bladder cancer; Urethral cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 07 Aug 2015 Planned End Date changed from 1 Jun 2013 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 07 Aug 2015 Planned primary completion date changed from 1 Jun 2013 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top